Xencor (XNCR) Following XmAb819 Webcast Plans, Is The Pipeline Narrative Starting To Look Undervalued?

Xencor (XNCR) is moving back into focus after the company set an October 26 webcast to walk investors through Phase 1 data for its XmAb819 kidney cancer program and outlined a 2027 registration study.

Recent trading reflects that backdrop. Xencor’s share price has rallied 7.6% over the past day and 27.8% across 90 days, contributing to a 67.2% year to date share price return. The 1 year total shareholder return of 71.9% points to strong momentum building around the pipeline story.

Capitalize on the momentum around Xencor by scanning a hand-picked 21 high quality undiscovered gems that could be setting up for their own catalyst driven moves.

Xencor now appears to be a stronger story, not just a hotter ticker. After a move like this, are you paying for a quality pipeline or overpaying for excitement around XmAb819 and the broader antibody portfolio?

Most Popular Narrative: 21% Undervalued

Xencor's most followed narrative pegs fair value at about $31.42 a share compared with the recent $24.94 close. This puts the focus firmly on whether the antibody platform can deliver enough future cash flows to back that gap.

The robust and flexible XmAb platform allows for modular drug development and the creation of differentiated assets, expected to reduce development costs and timelines, directly benefiting future operating margins and net profitability. Clinical trial strategy emphasizes efficient dose ranging and selection, ongoing biomarker efforts, and combination-therapy optionality, positioning the company to respond rapidly to evolving standards of care and maximize the commercial potential of its pipeline, with positive implications for recurring revenue and ultimate earnings leverage.

See why 8 investors see Xencor as 21% undervalued.

Result: Fair Value of $31.42 (UNDERVALUED)

Still, the Xencor story can change quickly if XmAb819 data underwhelms or if crowded TL1A competition makes it harder to translate the platform into revenue.

Find out about the key risks to this Xencor narrative.

Next Steps

If the mixed optimism and caution around Xencor feels familiar, let it be a prompt to act promptly, review the details, and form your own stance based on the underlying data and context, starting with 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Xencor?

Do not stop with Xencor. Use the screener to surface other opportunities that match your style before the next round of catalysts is already priced in.

• Target resilient cash generators by scanning a list of solid balance sheet and fundamentals (25 results) that can help anchor your portfolio when sentiment swings.
• Hunt for mispriced potential with a curated 34 high quality undervalued stocks that flags companies where fundamentals and current prices are out of sync.
• Stack income and stability by reviewing a focused 8 dividend fortresses built for investors who want meaningful yield backed by underlying business strength.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com